Manhattan Scientifics, Inc. (MHTX) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Manhattan Scientifics, Inc. (MHTX), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 46/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026Manhattan Scientifics, Inc. (MHTX) Sağlık ve Boru Hattı Genel Bakışı
Manhattan Scientifics, Inc. operates as a technology incubator specializing in nano-technologies and nano-medicine within the healthcare sector. The company focuses on the development and commercialization of life-enhancing technologies, primarily in the United States, facing competition from established medical device companies and other emerging technology firms.
Yatırım Tezi
Manhattan Scientifics, Inc. presents a high-risk, high-reward investment opportunity due to its focus on early-stage nano-technologies and nano-medicine. The company's success is contingent on its ability to successfully develop and commercialize its technologies, which face significant regulatory and market hurdles. With a market capitalization of $0.00B and a negative P/E ratio of -0.05, the company's valuation is highly speculative. Key value drivers include successful clinical trials and regulatory approvals for its nano-medicine technologies. Upcoming catalysts include potential partnerships and licensing agreements. Potential risks include the high beta of 9.94, indicating extreme volatility, and the challenges of operating in the competitive medical device industry.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Manhattan Scientifics operates as a technology incubator, focusing on early-stage development of nano-technologies and nano-medicine.
- The company's market capitalization is $0.00B, reflecting its early stage and speculative nature.
- Manhattan Scientifics has a negative P/E ratio of -0.05, indicating it is not currently profitable.
- The company's beta is 9.94, suggesting very high volatility compared to the market.
- Manhattan Scientifics does not offer a dividend, typical for growth-focused companies in the technology sector.
Rakipler & Benzerleri
Güçlü Yönler
- Focus on innovative nano-technologies and nano-medicine.
- Potential for high growth in emerging markets.
- Early-stage access to promising technologies.
Zayıflıklar
- Limited financial resources and small market capitalization.
- Dependence on successful development and commercialization of technologies.
- High risk associated with early-stage ventures.
Katalizörler
- Upcoming: Potential partnerships with pharmaceutical companies for drug delivery systems.
- Upcoming: Progress in clinical trials for nano-medicine applications.
- Upcoming: Regulatory approvals for new medical devices.
- Ongoing: Continued research and development in nano-technologies.
- Ongoing: Efforts to secure government funding and grants.
Riskler
- Potential: Failure to obtain regulatory approvals for its technologies.
- Potential: Intense competition from established medical device companies.
- Potential: Limited financial resources to support research and development.
- Ongoing: High volatility in stock price due to its small market capitalization.
- Ongoing: Dependence on successful commercialization of its technologies.
Büyüme Fırsatları
- Advancements in Nano-Medicine: The global nano-medicine market is projected to reach billions of dollars by 2030, driven by the increasing demand for targeted drug delivery and personalized medicine. Manhattan Scientifics can capitalize on this trend by focusing on developing innovative nano-medicine solutions for chronic diseases and cancer treatment. Successful clinical trials and regulatory approvals could significantly increase the company's valuation and market share. The timeline for realizing this opportunity depends on the progress of ongoing research and development efforts and the speed of regulatory reviews.
- Strategic Partnerships and Licensing Agreements: Manhattan Scientifics can accelerate its growth by forming strategic partnerships with larger pharmaceutical and medical device companies. These partnerships can provide access to funding, expertise, and distribution channels. Licensing agreements for its nano-technology platforms can generate revenue and validate the company's technology. The timeline for securing these partnerships depends on the company's ability to demonstrate the value and potential of its technologies. This strategy is ongoing as the company seeks to expand its network and market reach.
- Expansion into New Therapeutic Areas: Manhattan Scientifics can expand its focus beyond its current areas of interest and explore new therapeutic applications for its nano-technologies. This could include developing solutions for neurological disorders, cardiovascular diseases, and infectious diseases. The market for these therapeutic areas is substantial, and successful expansion could significantly increase the company's growth potential. This expansion is a long-term opportunity that requires significant investment in research and development.
- Government Funding and Grants: Manhattan Scientifics can leverage government funding and grants to support its research and development efforts. Government agencies such as the National Institutes of Health (NIH) and the National Science Foundation (NSF) offer grants for innovative research in nano-technology and nano-medicine. Securing these grants can provide non-dilutive funding and validate the company's technology. The timeline for securing these grants depends on the company's ability to submit competitive proposals and meet the eligibility criteria.
- Intellectual Property Protection: Manhattan Scientifics can strengthen its competitive advantage by securing strong intellectual property protection for its technologies. This includes filing patents for its nano-materials, drug delivery systems, and manufacturing processes. Strong intellectual property protection can prevent competitors from copying its technologies and provide a barrier to entry. This is an ongoing effort as the company continues to innovate and develop new technologies.
Fırsatlar
- Strategic partnerships with larger pharmaceutical and medical device companies.
- Expansion into new therapeutic areas and applications.
- Government funding and grants for research and development.
Tehditler
- Intense competition from established medical device companies.
- Stringent regulatory requirements and lengthy approval processes.
- Potential for technology obsolescence and market disruption.
Rekabet Avantajları
- Proprietary nano-technology platforms.
- Expertise in nano-medicine and targeted drug delivery.
- Early-stage access to innovative technologies.
MHTX Hakkında
Manhattan Scientifics, Inc., established in 1992 and based in New York City, functions as a technology incubator dedicated to the advancement and commercialization of life-enhancing technologies. The company's primary focus lies within the realms of nano-technologies and nano-medicine, where it seeks to develop and bring to market innovative solutions for various healthcare challenges. Originally named Grand Enterprises, Inc., Manhattan Scientifics has evolved to concentrate on identifying, developing, and commercializing early-stage technologies with high growth potential. The company's business model revolves around investing in and nurturing promising technologies until they reach a stage where they can be either spun off into separate entities, licensed to larger corporations, or further developed in-house. Manhattan Scientifics operates primarily within the United States, targeting opportunities where nano-scale technologies can provide significant improvements in medical treatments, diagnostics, and other healthcare applications. The company's success hinges on its ability to identify and develop groundbreaking technologies, navigate the complex regulatory landscape of the medical device industry, and secure the necessary funding to bring these innovations to market.
Ne Yaparlar
- Develops nano-technologies for medical applications.
- Focuses on nano-medicine for targeted drug delivery.
- Incubates early-stage technologies with high growth potential.
- Seeks to commercialize life-enhancing technologies.
- Invests in promising technologies until they are ready for market.
- Aims to improve medical treatments and diagnostics through innovation.
İş Modeli
- Invests in early-stage nano-technology and nano-medicine companies.
- Develops and commercializes innovative healthcare solutions.
- Generates revenue through licensing agreements and potential spin-offs.
Sektör Bağlamı
Manhattan Scientifics operates within the medical device industry, which is characterized by rapid innovation, stringent regulatory requirements, and intense competition. The market for nano-medicine is still in its nascent stages but is projected to experience significant growth in the coming years, driven by advancements in nanotechnology and increasing demand for targeted drug delivery systems. The company competes with established medical device companies and other emerging technology firms. Success in this industry requires significant investment in research and development, strong intellectual property protection, and the ability to navigate the complex regulatory landscape.
Kilit Müşteriler
- Pharmaceutical companies seeking innovative drug delivery systems.
- Medical device manufacturers looking to incorporate nano-technologies.
- Healthcare providers seeking advanced diagnostic and treatment tools.
Finansallar
Grafik & Bilgi
Manhattan Scientifics, Inc. (MHTX) hisse senedi fiyatı: Price data unavailable
Son Haberler
MHTX için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
MHTX için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
MHTX için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, MHTX'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Emmanuel Tsoupanarias
CEO
Emmanuel Tsoupanarias serves as the CEO of Manhattan Scientifics, Inc. His background includes experience in managing and developing early-stage technology companies. He has a track record of identifying and nurturing promising technologies in the healthcare sector. His expertise lies in strategic planning, business development, and financial management. He is responsible for overseeing the company's operations, driving its growth strategy, and building relationships with key stakeholders.
Sicil: Under Emmanuel Tsoupanarias's leadership, Manhattan Scientifics has focused on advancing its nano-technology and nano-medicine initiatives. Key achievements include securing funding for research and development, forming strategic partnerships, and advancing the company's technology pipeline. He has also overseen the company's efforts to protect its intellectual property and navigate the regulatory landscape. His leadership is focused on driving innovation and creating long-term value for shareholders.
MHTX OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that Manhattan Scientifics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies that are distressed, early-stage, or have chosen not to meet the listing requirements of higher tiers.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure and transparency.
- Potential for high price volatility due to low liquidity.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight and investor protection.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or investigations.
- Company has been in operation since 1992.
- Focus on developing innovative technologies in nano-medicine.
- CEO with experience in managing early-stage technology companies.
Manhattan Scientifics, Inc. Hissesi: Cevaplanan Temel Sorular
MHTX için değerlendirilmesi gereken temel faktörler nelerdir?
Manhattan Scientifics, Inc. (MHTX) şu anda yapay zeka skoru 46/100, düşük puanı gösteriyor. Temel güçlü yan: Focus on innovative nano-technologies and nano-medicine.. İzlenmesi gereken birincil risk: Potential: Failure to obtain regulatory approvals for its technologies.. Bu bir finansal tavsiye değildir.
MHTX MoonshotScore'u nedir?
MHTX şu anda MoonshotScore'da 46/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
MHTX verileri ne sıklıkla güncellenir?
MHTX fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler MHTX hakkında ne diyor?
MHTX için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
MHTX'a yatırım yapmanın riskleri nelerdir?
MHTX için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Failure to obtain regulatory approvals for its technologies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
MHTX'ın P/E oranı nedir?
MHTX için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için MHTX'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
MHTX aşırı değerli mi, yoksa düşük değerli mi?
Manhattan Scientifics, Inc. (MHTX)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
MHTX'ın temettü verimi nedir?
Manhattan Scientifics, Inc. (MHTX) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.